Article
Nivolumab Linked to Nephritis in Melanoma
In this case report, researchers analyze a reoccurrence of kidney inflammation in a patient being treated for metastatic melanoma with...
Author Affiliations
Mr. Tam is a medical student at the University of California, San Francisco School of Medicine. Dr. Yuan is a Clinical Research Fellow, Dr. Mauro is a Professor, and Dr. Arron is an Associate Professor, all in the Department of Dermatology at the University of California San Francisco. Dr. Arron also is the Chief of Mohs Micrographic Surgery and Dr. Mauro is the Interim Deputy Chief of Staff, both at San Francisco Veterans Affairs Health System. Dr. Dellavalle is a Professor in the Department of Dermatology at the University of Colorado Denver and the Chief of the Dermatology Service at the Denver Veteran Affairs Medical Center.
Author Disclosures
The authors report no actual or potential conflicts of interest with regard to this article.
Disclosure
The opinions expressed herein are those of the authors and do not necessarily reflect those of Federal Practitioner, Frontline Medical Communications Inc., the U.S. Government, or any of its agencies.
Respondents at sites that provided MMS rated various aspects of care (Figure 1).
Sixteen (84%) reported that MMS was received in a reasonable amount of time, 15 (79%) that facilities and resources for MMS were adequate, 13 (68%) that they themselves were capable of meeting the demands of MMS, 11 (58%) that their sites did not have enough Mohs surgeons, 11 (58%) that the number of support staff for MMS was sufficient, and 14 (74%) that patients had to travel a long distance to access MMS.Respondents from sites that purchased MMS care from non-VA medical care rated surgery availability and ease of patient follow-up (Figure 2).
Eighteen (66.7%) reported that referred patients received MMS in a reasonable amount of time, 7 (25.9%) that patients had to travel a long distance to the fee-basis/non-VA care facility, 12 (44.4%) that follow-up after fee-basis/non-VA care for MMS was difficult, and 25 (83.3%) that follow-up after activation of Veterans Choice was difficult.Related: Getting a Better Picture of Skin Cancer
Skin cancer is highly prevalent in the veteran patient population, and each year treatment by the VHA requires considerable spending.1 The results of this cross-sectional survey characterize veterans’ access to MMS within the VHA and provide a 10-year update to the survey findings of Karen and colleagues.11 Compared with their study, this survey offers a more granular description of practices and facilities as well as comparisons of VHA care with care purchased from outside sources. In outlining the state of MMS care within the VHA, this study highlights progress made and provides the updated data needed for continued efforts to optimize care and resource allocation for patients who require MMS within the VHA.
Although the number of VHA sites that provide MMS has increased over the past 10 years—from 11 sites in 9 states in 2007 to 19 sites in 13 states now—it is important to note that access to MMS care highly depends on geographic location.11 The VHA sites that provide MMS are clustered in major cities along the coasts. Four states (California, Florida, New York, and Texas) had > 1 MMS site, whereas most other states did not have any. In addition, only 1 MMS site served all of the northwest U.S. To ensure the anonymity of survey respondents, the authors did not further characterize the regional distribution of MMS sites.
Despite the increase in MMS sites, the number of MMS cases performed within the VHA seemed to have decreased. An estimated 8,310 cases were performed within the VHA in 2006,which decreased to 6,686 in 2015.11 Although these are estimates, the number of VHA cases likely decreased because of a rise in purchased care. Reviewing VHA electronic health records, Yoon and colleagues found that 19,681 MMS cases were performed either within the VHA or at non-VA medical care sites in 2012.1 Although the proportions of MMS cases performed within and outside the VHA were not reported, clearly many veterans had MMS performed through the VHA in recent years, and a high percentage of these cases were external referrals. More study is needed to further characterize MMS care within the VHA and MMS care purchased.
The 19 sites that provided MMS were evenly divided by volume: high (> 500 cases/y), medium (200-500 cases/y), and low (< 200 cases/y). Case volume correlated with the numbers of surgeons, nurses, and support staff at each site. Number of patient rooms dedicated to MMS at each site was not correlated with case volume; however, not ascertaining the number of days per week MMS was performed may have contributed to the lack of observed correlation.The majority of Mohs surgeons (25; 89.3%) within the VHA were affiliated with academic programs, which may partly explain the uneven geographic distribution of VHA sites that provide MMS (dermatology residency programs typically are in larger cities). The majority of Mohs surgeons were fellowship-trained through the ACMS or the ACGME. As the ACGME first began accrediting fellowship programs in 2003, younger surgeons were more likely to have completed this fellowship. According to respondents from sites that did not provide MMS, noncompetitive VHA salaries might be a barrier to Mohs surgeon recruitment. If a shift to providing more MMS care within the VHA were desired, an effective strategy could be to raise surgeon salaries. Higher salaries would bring in more Mohs surgeons and thereby yield higher MMS case volumes at VHA sites.
However, whether MMS is best provided for veterans within the VHA or at outside sites through referrals warrants further study. More than 60% of sites provided access to MMS through purchased care, either by fee-basis/non-VA medical care referrals or by the patient-elected Veterans Choice program. According to 84.2% of respondents at MMS sites and 66.7% of respondents at non-MMS sites, patients received care within a reasonable amount of time. In addition, respondents at MMS sites estimated longer patient travel distance for surgery. Respondents reported being concerned about coordination of care and follow-up for patients who received MMS outside the VHA. Other than referrals to outside sites for MMS, current triage practices include referral to other surgical specialties within the VHA, predominantly ear, nose, and throat and plastic surgery, for WLE. Given that access to on-site MMS varies significantly by geographic location, on-site MMS may be preferable in some locations, and external referrals in others. Based on this study's findings, on-site MMS seems superior to external referrals in all respects except patient travel distance. More research is needed to determine the most cost-effective triage practices. One option would be to have each VISN develop a skin cancer care center of excellence that would assist providers in appropriate triage and management.
In this case report, researchers analyze a reoccurrence of kidney inflammation in a patient being treated for metastatic melanoma with...
New targeted treatments and therapies for metastatic melanoma are improving patient prognosis and survival.
Development of a new dermatologic device allows surgeons to assess skin cancers with greater ease and accuracy.